CytomX Therapeutics (CTMX) Tops Q1 EPS by 25c

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of $0.17, $0.25 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $41.46 million versus the consensus estimate of $19.92 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Circle Internet Group (CRCL) PT Lowered to $100 at US Tiger Securities
• Sherwin-Williams climbs 18% off 52-week low as Citi sets $380 target